MedTrace Logo

Optimized Therapy in Severe Traumatic Brain Injured Patients

NCT02130674 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-05-06

No results posted yet for this study

Summary

Severe traumatic brain injury is associated with life-threatening and incapacitating secondary injury.

Contemporary therapeutic interventions are aimed at preventing and treating secondary damage. In this context, improved cerebral metabolism is an important target in modern neurointensive care.

The main hypothesis is that continuous intravenous infusion of glutamyl-alanyl dipeptide restores disturbed brain metabolism following severe traumatic brain injury.

Conditions

Interventions

DRUG

Dipeptiven

two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Fresenius Kabi

    collaborator INDUSTRY

  • University Hospital, Zürich

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • John F Stover, MD · University of Zurich

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02130674 on ClinicalTrials.gov